<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356641</url>
  </required_header>
  <id_info>
    <org_study_id>KCA2011/APAC</org_study_id>
    <nct_id>NCT01356641</nct_id>
  </id_info>
  <brief_title>Antibiotic Treatment Alone for Acute Simple Appendicitis in Children</brief_title>
  <official_title>Antibiotic Treatment Alone for Acute Simple Appendicitis in Children; a Prospective Cohort Study Part of the Antibiotic Versus Primary Appendectomy in Children (APAC) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramon R. Gorter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Red Cross Hospital Beverwijk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flevoziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University of Amsterdam</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Appendectomy for acute appendicitis has recently been questioned as being the only correct&#xD;
      treatment for appendicitis. Appendectomy has been reported to have significant early and late&#xD;
      morbidity. This can be avoided with antibiotic treatment alone. Moreover, better quality of&#xD;
      life and lower costs have been associated with antibiotic treatment alone. Five clinical&#xD;
      trials in selected patients (males, older than 18 years) comparing appendectomy and&#xD;
      antibiotic treatment alone as primary mode of treatment found that antibiotic treatment alone&#xD;
      is safe and effective in 48-95% of the patients Conclusive evidence with regard to the&#xD;
      efficacy of antibiotic treatment alone in children with proven acute appendicitis however is&#xD;
      lacking. We propose a prospective cohort study to answer the following questions:&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      What is the complication rate of the initial antibiotic treatment strategy (IATS) for acute&#xD;
      simple appendicitis (radiological proven) in children aged 7-17 years old?&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      What is the complication rate of the direct appendectomy treatment strategy (DATS) for acute&#xD;
      simple appendicitis (radiological proven) in children aged 7-17 years old?&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Prospective multi-centre pilot cohort study.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Children (7-17years old) with radiologically proven simple appendicitis.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Initial antibiotic treatment strategy (IATS): Intravenous administration of&#xD;
      amoxicillin/clavulanic acid 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a&#xD;
      day) and gentamicin 7mg/kg once daily will be given for 48 hours. If possible the antibiotics&#xD;
      will be switched to oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a&#xD;
      day) for in total 7 days. If after 72 hours, the patient does not meet the predefined&#xD;
      criteria, an appendectomy will be performed.&#xD;
&#xD;
      Control group:&#xD;
&#xD;
      The control group will consist of patients, who do not want the antibiotic treatment. Their&#xD;
      medical files will be monitored prospectively. In addition they will be scheduled for an&#xD;
      extra outpatient clinic follow up (8 weeks after discharge), extra telephone contact one year&#xD;
      after discharge and asked to fill out quality of life questionnaires.&#xD;
&#xD;
      Primary parameters/endpoints:&#xD;
&#xD;
      Safety of initial antibiotic treatment defined as:&#xD;
&#xD;
      Occurrence of major complications, such as:&#xD;
&#xD;
      A. Anaphylactic shock and other allergic reaction to antibiotics administered b. Recurrent&#xD;
      appendicitis within 8 weeks c. Recurrent appendicitis within one year after discharge d.&#xD;
      Development of perforated appendicitis e. Occurrence of major complaints after delayed&#xD;
      appendectomy such as intra-abdominal abscess (IAA), stumpleakage, superficial site infection&#xD;
      (SSI), anaesthesia related complications, secondary bowel obstruction (SBO), re-admission,&#xD;
      need for re-intervention f. Re-admission g. Re-intervention other than delayed appendectomy&#xD;
&#xD;
      Secondary outcome parameters Major complications associated with appendectomy&#xD;
&#xD;
        1. Stumpleakage&#xD;
&#xD;
        2. Intra-abdominal abscess (IAA)&#xD;
&#xD;
        3. Secondary bowel obstruction (SBO)&#xD;
&#xD;
        4. Superficial site infection (SSI)&#xD;
&#xD;
        5. Need for secondary operation&#xD;
&#xD;
        6. Need for other re-intervention&#xD;
&#xD;
        7. Re-admission&#xD;
&#xD;
        8. Anaesthesia related complication&#xD;
&#xD;
        9. Pneumonia&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness:&#xD;
&#xD;
        1. Risks of participation: Need for delayed operation, recurrent appendicitis. Risks that&#xD;
           are also present in case of non-participation: Allergic reaction to antibiotics, known&#xD;
           appendectomy associated complications.&#xD;
&#xD;
        2. Burden of participation: Extra admission day (in comparison with appendectomy),&#xD;
           ultrasonography after 48 hours (extra procedure), outpatient follow up (two extra&#xD;
           visits), filling out QOL questionnaires. Burden also present in case of&#xD;
           non-participation: Intravenous access (normal procedure), daily blood samples (normal&#xD;
           procedure). Regarding the control group, the burden will consist of an extra outpatient&#xD;
           clinic follow up (8 weeks after discharge), extra telephone contact one year after&#xD;
           discharge and fill out quality of life questionnaires.&#xD;
&#xD;
        3. Benefit of participation: Avoidance of surgery and its related early and late morbidity,&#xD;
           potential better quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of initial antibiotic treatment strategy</measure>
    <time_frame>0-12 months</time_frame>
    <description>Occurrence of major complications, such as:&#xD;
A. Anaphylactic shock and other allergic reaction to antibiotics administered b. Recurrent appendicitis within 8 weeks c. Recurrent appendicitis within one year after discharge d. Development of perforated appendicitis e. Occurrence of major complaints after delayed appendectomy such as intra-abdominal abscess (IAA), stumpleakage, superficial site infection (SSI), anaesthesia related complications, secondary bowel obstruction (SBO), re-admission, need for re-intervention f. Re-admission g. Re-intervention other than delayed appendectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the direct appendectomy treatment strategy</measure>
    <time_frame>0-12 months</time_frame>
    <description>Major complications associated with appendectomy&#xD;
Stumpleakage&#xD;
Intra-abdominal abscess (IAA)&#xD;
Secondary bowel obstruction (SBO)&#xD;
Superficial site infection (SSI)&#xD;
Need for secondary operation&#xD;
Need for other re-intervention&#xD;
Re-admission&#xD;
Anaesthesia related complication&#xD;
Pneumonia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Appendicitis</condition>
  <arm_group>
    <arm_group_label>Antibiotic treatment alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration:&#xD;
Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7mg/kg once daily&#xD;
Oral administration of:&#xD;
Amoxicillin/clavulanic acid 50/12.5 mg/kg/day (in three doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Appendectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routine appendectomy either laparoscopic or open depending on the surgeon's preference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic treatment alone</intervention_name>
    <description>Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg</description>
    <arm_group_label>Antibiotic treatment alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Appendectomy</intervention_name>
    <description>Appendectomy either open or laparoscopic depending on the surgeon's preference</description>
    <arm_group_label>Appendectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 7-17 years&#xD;
&#xD;
          2. Radiologically confirmed simple appendicitis, defined as:&#xD;
&#xD;
             a. Clinical findings: i. Unwell, but not generally ill ii. Localized tenderness in the&#xD;
             right iliac fossa region iii. Normal/hyperactive bowel sounds iv. No guarding v. No&#xD;
             mass palpable b. Ultrasonography: i. Incompressible appendix with an outer diameter of&#xD;
             ≥6 mm ii. Hyperaemia within the appendiceal wall iii. Without fecalith iv.&#xD;
             Infiltration of surrounding fat v. No signs of perforation vi. No signs of intra&#xD;
             abdominal abscess/phlegmon&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients with severe general illness at time of presentation:&#xD;
&#xD;
               1. Generalized peritonitis defined as:&#xD;
&#xD;
                  Diffuse inflammation of the peritoneum with clinical signs consisting of&#xD;
                  increasing abdominal pain, generalized tenderness, diffuse abdominal rigidity,&#xD;
                  sinus tachycardia, signs of paralytic ileus&#xD;
&#xD;
               2. Severe sepsis or septic shock, as defined by the international paediatric sepsis&#xD;
                  consensus conference [39]. See attachment 1.&#xD;
&#xD;
               3. Signs of complex appendicitis&#xD;
&#xD;
          2. Children with a fecalith on ultrasonography.&#xD;
&#xD;
          3. Patients with serious associated conditions or malformations such as:&#xD;
&#xD;
               1. Congenital or acquired cardiac or pulmonary disease with significant hemodynamic&#xD;
                  consequences&#xD;
&#xD;
               2. Immunodeficiency&#xD;
&#xD;
               3. Malignancy&#xD;
&#xD;
               4. Homozygous sickle cell disease&#xD;
&#xD;
               5. Metabolic disorders&#xD;
&#xD;
          4. Patient with documented type 1 allergy to the antibiotics used&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon R Gorter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo A Heij, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic medical center of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University medical center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Cross Hospital</name>
      <address>
        <city>Beverwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>VU University of Amsterdam</investigator_affiliation>
    <investigator_full_name>Ramon R. Gorter</investigator_full_name>
    <investigator_title>MD, PhD candidate</investigator_title>
  </responsible_party>
  <keyword>Antibiotic treatment</keyword>
  <keyword>Non perforated appendicitis</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Appendicitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

